Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Genfit SA ( (GNFT) ) has shared an update.
On February 14, 2025, GENFIT announced amendments to the terms of its dual proposal to the 2025 OCEANEs bondholders, in conjunction with a royalty financing deal with HealthCare Royalty. The amendments include repurchasing bonds at EUR 32.75 each or paying a consent fee of EUR 0.90 per outstanding bond, conditional on bondholder approval and the closing of the royalty financing. This move is aimed at extending GENFIT’s cash runway and securing obligations under the royalty financing, potentially impacting GENFIT’s financial strategy and stakeholder interests.
More about Genfit SA
GENFIT is a biopharmaceutical company focused on developing treatments for rare and life-threatening liver diseases, such as Acute-on-Chronic Liver Failure and cholangiocarcinoma. With a strong scientific heritage, GENFIT has a diversified R&D portfolio and expertise in high-potential molecule development. The company also has a diagnostics franchise and is headquartered in Lille, France, with offices in Paris, Zurich, and Cambridge, MA. GENFIT is listed on Nasdaq and Euronext.
YTD Price Performance: 9.66%
Average Trading Volume: 8,127
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $203.5M
Find detailed analytics on GNFT stock on TipRanks’ Stock Analysis page.
